RadNet revenue rose 25%, yet shareholder profit nearly halved. Where did the earnings go?

RadNet, Inc. (NASDAQ: RDNT) reported record second-quarter 2026 revenue of US$622.7 million, up 25.0%, and record adjusted EBITDA of US$99.7 million, up 22.7%. Operating income also increased 27.8% to US$39.5 million. Yet net income attributable to RadNet common shareholders fell 47.9% to US$7.5 million, creating a sharper earnings contradiction than the headline growth rates suggest.

The reconciliation is mechanical. RadNet generated US$8.59 million more operating income than a year earlier, but other expenses increased by US$5.83 million, the income-tax provision increased by US$5.54 million and net income attributable to noncontrolling interests increased by US$4.14 million. Those three movements totalled US$15.51 million and more than absorbed the operating improvement, leaving common-shareholder profit US$6.92 million lower.

The ownership allocation is the least visible part of the bridge. Total company net income was US$20.3 million, of which US$12.7 million, or 62.8%, was attributable to noncontrolling interests and US$7.5 million, or 37.2%, was attributable to RadNet common shareholders. A year earlier, 37.2% was attributed to noncontrolling interests, so the mix reversed even as the imaging network expanded and delivered stronger operating results.

RadNet’s Digital Health business adds a second test. Quarterly revenue increased 56.5% to US$32.4 million and annual recurring revenue almost doubled to US$105.5 million, but segment adjusted EBITDA declined 27.2% to US$2.5 million. The question is how quickly partnership growth, acquisitions and artificial intelligence investment can translate into durable earnings attributable to the listed company.

How did stronger operations end with 48% less profit for RadNet shareholders?

Revenue increased by US$124.5 million and operating income rose from US$30.9 million to US$39.5 million. The operating margin improved modestly from 6.2% to 6.3%, while the Imaging Center segment’s adjusted EBITDA margin increased 17 basis points to 16.1%. The reversal occurred below operating income as total other expenses increased from US$7.0 million to US$12.9 million, including US$3.4 million of debt restructuring and extinguishment expense, although pre-tax income still rose 11.6% to US$26.6 million.

The tax provision then increased from US$0.8 million to US$6.4 million as the effective tax rate moved from 3.4% to 23.9%. Total net income consequently declined 12.1% to US$20.3 million. The final US$4.14 million increase in the allocation to noncontrolling interests converted that moderate company-wide decline into a 47.9% reduction in profit attributable to RadNet common shareholders.

Why was 62.8% of RadNet’s quarterly net income allocated elsewhere?

Noncontrolling interest is an accounting ownership allocation, not a quarterly cash distribution. RadNet consolidates subsidiaries it controls even when partners own an economic interest, then removes the partners’ share of earnings from the amount attributable to RadNet common shareholders. First-half cash distributions to noncontrolling interests were US$3.9 million, versus US$21.5 million of net income attributed to those interests, so the figures are not interchangeable.

RadNet’s 2025 annual report said 101 of the 368 imaging centres operated by consolidated subsidiaries at year-end were not wholly owned. It also cautioned that noncontrolling interests represent only part of the Imaging Center business and exclude the Digital Health segment, which was loss-making on a reported basis in 2025. For that reason, management did not expect changes in profit attributable to noncontrolling interests to correlate directly with consolidated operating or pre-tax income.

At June 30, RadNet said 157 of its 442 locations were held within health-system partnerships, supporting referral alignment and market expansion. That June disclosure is not directly comparable with the December 2025 count of 101 centres operated by consolidated, not-wholly-owned subsidiaries because the two figures use different dates and scopes. Neither count directly measures the quarterly noncontrolling-interest allocation, although partnership growth can strengthen the network without every dollar of consolidated profit belonging to RadNet common shareholders.

Why did RadNet Digital Health revenue rise while profitability weakened?

Digital Health produced US$32.4 million of second-quarter revenue, including intersegment revenue, compared with US$20.7 million a year earlier. Segment adjusted EBITDA declined from US$3.4 million to US$2.5 million, reducing the adjusted EBITDA margin from 16.4% to 7.6%. RadNet attributed the decline predominantly to additional sales, marketing, customer-service and implementation headcount intended to support the growth pipeline.

The half-year divergence was larger. Digital Health revenue increased 54.1% to US$61.5 million, while adjusted EBITDA fell 46.9% to US$3.8 million and margin declined from 17.8% to 6.1%. RadNet is adding infrastructure ahead of anticipated revenue, but the growth has not yet produced operating leverage.

Annual recurring revenue reached US$105.5 million, up 97.2% year on year and 8.9% from March, while first-half new total contract value reached US$37 million. Neither is recognised revenue: one annualises active recurring contracts and the other can convert over multiple periods. They improve visibility without proving the timing of profit conversion.

Can RadNet’s unchanged Digital Health guidance deliver the required H2 step-up?

RadNet retained full-year Digital Health guidance of US$135 million to US$145 million of revenue and US$10 million to US$12 million of adjusted EBITDA before specified non-capitalised research and development. After first-half revenue of US$61.5 million, the range requires US$73.5 million to US$83.5 million in H2, representing a 19.5% to 35.8% increase from H1.

The profit hurdle is steeper. Subtracting first-half adjusted EBITDA of US$3.8 million produces an illustrative H2 requirement of US$6.2 million to US$8.2 million, or 64.5% to 117.4% above H1. At the midpoint, Digital Health needs approximately US$7.2 million of H2 adjusted EBITDA, a 90.9% sequential increase, on US$78.5 million of revenue. The implied second-half margin is about 9.2%, compared with 6.1% in the first half.

RadNet expects its recently cleared breast-ultrasound artificial intelligence solution to be introduced across its centres by year-end, with revenue and cost-saving contributions during H2. The route is credible, but regulatory clearance and contract value establish opportunity while implementation determines when the economics reach reported results.

How much protection does RadNet’s core imaging network provide?

The Imaging Center segment remains the financial engine. Its second-quarter adjusted EBITDA increased 24.8% to US$97.2 million, accounting for 97.5% of total company adjusted EBITDA. Aggregate advanced-imaging volumes increased 21.2%, while same-centre advanced-imaging volumes rose 9.6%. PET and computed-tomography volumes grew faster than routine imaging, lifting advanced procedures to 29.9% of total volume from 27.5%.

Magnetic resonance imaging, computed tomography and PET represented 64.7% of Q2 payments despite comprising less than one-third of procedures. Higher-value modality mix, same-centre demand and acquisitions are therefore improving the earnings capacity of the physical network.

Management revised the Imaging Center outlook after Q2, raising full-year revenue guidance to US$2.37 billion to US$2.42 billion, adjusted EBITDA guidance to US$345 million to US$358 million and free-cash-flow guidance to US$115 million to US$125 million. Digital Health guidance remained unchanged, indicating that the upgrade rests on the core imaging business rather than an accelerated artificial intelligence profit assumption.

Do RadNet’s adjusted earnings resolve the common-shareholder profit paradox?

Adjusted earnings present a less severe decline, but they do not remove it. RadNet reported adjusted earnings attributable to common shareholders of US$23.2 million, down 10.0%, and adjusted diluted earnings per share of US$0.29, down 14.7%. Diluted weighted-average shares increased 4.2%, adding a per-share headwind beyond the decline in adjusted earnings.

The US$15.6 million after-tax gap between reported and adjusted common earnings included Digital Health intangible amortisation, acquisition transaction costs, specified DeepHealth research and development and debt-restructuring expense, partly offset by a contingent-consideration gain. The exclusions may isolate operating trends, but their scale means reported and adjusted results answer different questions.

There is also a comparative trap. RadNet added US$2.0 million of DeepHealth intangible amortisation to the Q2 2025 adjusted comparator. The current release therefore compares US$23.2 million and US$0.29 with recast figures of US$25.7 million and US$0.34, not the US$23.8 million and US$0.31 originally published. Readers comparing separate releases could otherwise calculate a smaller decline.

What does acquisition spending reveal about RadNet’s cash conversion?

First-half operating cash flow increased 6.9% to US$173.1 million. Subtracting US$126.2 million of property and equipment purchases and adding US$0.7 million of sale proceeds leaves US$47.6 million before acquisitions and financing. This is a simple comparison, not RadNet’s defined free cash flow, which starts with adjusted EBITDA and subtracts capital expenditure and cash interest.

Acquisition cash outflow net of acquired cash reached US$315.7 million, versus US$32.0 million a year earlier. Net new-debt proceeds were US$248.9 million after a US$250 million incremental term loan intended for acquisitions, expansion, partnerships and general purposes. The proceeds equalled 78.9% of acquisition outflow as a scale comparison, not a one-for-one funding claim.

Balance-sheet debt carrying value increased 22.3% to US$1.33 billion, cash declined 5.3% to US$726.3 million and the company reported net debt to adjusted EBITDA of 1.8 times. Goodwill and other intangible assets increased by a combined US$311.6 million, or 29.5%, from year-end and represented 32.4% of total assets. Liquidity remains substantial, but acquisition integration and cash conversion now have greater importance because more of the balance sheet rests on purchased businesses and expected future benefits.

What was RadNet stock signalling before the Q2 results reached the market?

RadNet shares closed at US$72.39 on August 7, up 13.5% over five trading sessions, 10.4% from July 8, 1.5% from December 31 and 35.7% from August 8, 2025. The close was 15.7% below the 52-week high and 42.4% above the 52-week low. Because RadNet released Q2 results on Sunday, August 9, the August 7 close does not represent the market’s reaction to the quarter.

Using the June-end share count and August 7 close gives an illustrative equity value of approximately US$5.69 billion. Trailing revenue was about US$2.27 billion, producing a mechanical price-to-sales comparison of 2.51 times. Adding balance-sheet debt carrying value and subtracting cash produces an enterprise-value comparison of approximately 18.8 times trailing adjusted EBITDA before lease liabilities.

The pre-release pattern was positive but below the 52-week high. The valuation needs imaging-centre growth, partnerships and recurring revenue to produce stronger common-shareholder cash earnings, while delayed Digital Health margin recovery would increase the risk.

What do RadNet’s Q2 profit flows reveal for investors?

• RadNet’s Q2 revenue increased 25.0% and operating income rose 27.8%, but US$15.51 million of higher other expenses, taxes and noncontrolling-interest attribution more than absorbed the US$8.59 million operating gain, cutting common-shareholder net income by 47.9%.
• Noncontrolling interests were attributed 62.8% of total quarterly net income, up from 37.2% a year earlier. This is an ownership allocation rather than a cash distribution, and neither the 157 partnership locations nor the older 101-centre disclosure directly measures it.
• Digital Health revenue increased 56.5%, but adjusted EBITDA declined 27.2%. The midpoint of unchanged guidance requires approximately US$7.2 million of H2 adjusted EBITDA, 90.9% above the first-half result.
• Imaging Center adjusted EBITDA increased 24.8% to US$97.2 million and represented 97.5% of consolidated adjusted EBITDA, while adjusted common-shareholder earnings still declined 10.0% on the recast comparative basis.
• Acquisition cash outflow reached US$315.7 million, debt carrying value increased 22.3% and goodwill plus other intangible assets rose 29.5%. The August 7 share price preceded the Sunday results release and is not an earnings-reaction measure.

Can RadNet turn network growth into more profit for common shareholders?

RadNet’s second quarter validates the operating strategy more clearly than the common-shareholder earnings line. The imaging network generated strong same-centre and aggregate growth, advanced procedures gained share, Imaging Center adjusted EBITDA rose almost 25% and management raised the segment’s revenue, profit and cash-flow guidance. The health-system partnership model also gives RadNet a differentiated route to expand its footprint and embed DeepHealth products into clinical workflows.

The quarter shows why consolidated growth and listed-company earnings are not synonyms. A higher effective tax rate, debt-related expense and a larger noncontrolling-interest allocation transformed operating-income growth into a near-halving of reported common-shareholder profit. The partnership model is not defective, but its ownership economics matter when investors value RadNet on consolidated revenue and adjusted EBITDA.

Digital Health is the swing factor. Recurring revenue, new contracts, regulatory clearances and a broader artificial intelligence portfolio create substantial commercial optionality, yet first-half segment margin moved backwards and the second half requires a material EBITDA acceleration. If RadNet delivers the Digital Health guidance midpoint while its core imaging network maintains advanced-modality growth, the current investment phase can begin to look like operating leverage in waiting. If margins remain compressed while acquisitions, amortisation and partner allocations continue to widen the gap between consolidated performance and common-shareholder earnings, the record revenue headline will remain only part of the story.